CLCS (Cell Source) Shares Outstanding (EOP): 45.04 Mil (As of Dec. 2024)


CLCS Cell Source Inc CLCS
35 GF Score
Price $0.75
View Full Analysis

What is Cell Source Shares Outstanding (EOP)?

Cell Source CLCS -9.64% 35 Shares Outstanding (EOP) is 45.04 Mil as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cell Source's shares outstanding for the quarter that ended in Dec. 2024 was 45.04 Mil.

Cell Source's quarterly shares outstanding increased from Sep. 2024 (43.25 Mil) to Dec. 2024 (45.04 Mil). It means Cell Source issued new shares from Sep. 2024 to Dec. 2024 .

Cell Source's annual shares outstanding increased from Dec. 2023 (39.83 Mil) to Dec. 2024 (45.04 Mil). It means Cell Source issued new shares from Dec. 2023 to Dec. 2024 .


Cell Source  (OTCPK:CLCS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cell Source Shares Outstanding (EOP) Related Terms


Cell Source Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Cell Source's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Shares Outstanding (EOP) Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.54 34.36 36.08 39.83 45.04

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.83 41.02 41.94 43.25 45.04

CLCS vs EDSA, CTXR, ASBP: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Cell Source's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell Source Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cell Source's Shares Outstanding (EOP) falls into.


CLCS
35GF Score
Cell Source Inc CLCS
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 45.04 Mil mean?
Cell Source (CLCS) has a Shares Outstanding (EOP) of 45.04 Mil as of Dec. 2024. The total shares a company has outstanding, at period-end. View historical data on Cell Source and its competitors.
Is Cell Source's Shares Outstanding (EOP) too high?
Cell Source's current Shares Outstanding (EOP) is 45.04 Mil. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's Shares Outstanding (EOP) compare to EDSA and CTXR?
Cell Source's Shares Outstanding (EOP) of 45.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Cell Source and its competitors. Cell Source's current Shares Outstanding (EOP) is 45.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current Shares Outstanding (EOP) of 45.04 Mil. The current Shares Outstanding (EOP) is 45.04 Mil. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Cell Source (CLCS), the current Shares Outstanding (EOP) is 45.04 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price